IOL Chemicals and Pharmaceuticals Limited (IOLCP.NS)
INR 434.5
(7.04%)
INR 434.5
(7.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 327.6 Million INR | -58.95% |
| 2022 | 798.1 Million INR | 81.59% |
| 2021 | 439.5 Million INR | 1509.89% |
| 2020 | 27.3 Million INR | -95.41% |
| 2019 | 594.9 Million INR | -79.05% |
| 2018 | 2.84 Billion INR | -32.68% |
| 2017 | 4.21 Billion INR | -5.71% |
| 2016 | 4.47 Billion INR | -1.26% |
| 2015 | 4.53 Billion INR | 13.99% |
| 2014 | 3.97 Billion INR | 27.02% |
| 2013 | 3.12 Billion INR | -18.5% |
| 2012 | 3.83 Billion INR | 39.78% |
| 2011 | 2.74 Billion INR | -20.16% |
| 2010 | 3.44 Billion INR | 27.86% |
| 2009 | 2.69 Billion INR | 15.49% |
| 2008 | 2.33 Billion INR | 134.61% |
| 2007 | 993.24 Million INR | -3.01% |
| 2006 | 1.02 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 327.6 Million INR | 0.0% |
| 2023 FY | 327.6 Million INR | -58.95% |
| 2023 Q2 | 590.5 Million INR | 0.0% |
| 2023 Q3 | 327.6 Million INR | -44.52% |
| 2022 FY | 798.1 Million INR | 81.59% |
| 2022 Q4 | 798.1 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 879.8 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 439.5 Million INR | 1509.89% |
| 2021 Q4 | 439.5 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 412.4 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 27.3 Million INR | -95.41% |
| 2020 Q4 | 27.3 Million INR | 0.0% |
| 2020 Q2 | 245.5 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q4 | 594.9 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 986.9 Million INR | 0.0% |
| 2019 FY | 594.9 Million INR | -79.05% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 2.84 Billion INR | 0.0% |
| 2018 Q2 | 3.49 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 2.84 Billion INR | -32.68% |
| 2017 Q2 | 4.36 Billion INR | 0.0% |
| 2017 FY | 4.21 Billion INR | -5.71% |
| 2017 Q4 | 4.21 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 4.35 Billion INR | 0.0% |
| 2016 Q4 | 4.47 Billion INR | 0.0% |
| 2016 FY | 4.47 Billion INR | -1.26% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 4.53 Billion INR | 13.99% |
| 2015 Q2 | 4.31 Billion INR | 0.0% |
| 2015 Q4 | 4.53 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 3.19 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 3.97 Billion INR | 0.0% |
| 2014 FY | 3.97 Billion INR | 27.02% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 3.71 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 3.12 Billion INR | 0.0% |
| 2013 FY | 3.12 Billion INR | -18.5% |
| 2012 FY | 3.83 Billion INR | 39.78% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 5.11 Billion INR | 0.0% |
| 2012 Q4 | 3.83 Billion INR | 0.0% |
| 2011 FY | 2.74 Billion INR | -20.16% |
| 2010 FY | 3.44 Billion INR | 27.86% |
| 2009 FY | 2.69 Billion INR | 15.49% |
| 2008 FY | 2.33 Billion INR | 134.61% |
| 2007 FY | 993.24 Million INR | -3.01% |
| 2006 FY | 1.02 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | 77.099% |
| Ind-Swift Limited | 10.13 Billion INR | 96.769% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 90.157% |
| Sakar Healthcare Limited | 793.51 Million INR | 58.715% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.507% |
| Innova Captab Limited | 2.45 Billion INR | 86.634% |
| Divi's Laboratories Limited | 30 Million INR | -992.0% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -612.453% |
| Morepen Laboratories Limited | 289.99 Million INR | -12.969% |
| Mankind Pharma Limited | 2.07 Billion INR | 84.187% |
| Sequent Scientific Limited | 4.87 Billion INR | 93.283% |
| Wanbury Limited | 1.16 Billion INR | 71.876% |
| Laurus Labs Limited | 25.77 Billion INR | 98.729% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 94.845% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -91.043% |
| Alembic Limited | 91.5 Million INR | -258.033% |
| Hikal Limited | 8.17 Billion INR | 95.993% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 93.616% |
| Neuland Laboratories Limited | 953.89 Million INR | 65.657% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 91.326% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 97.339% |
| Themis Medicare Limited | 957.92 Million INR | 65.801% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 95.926% |
| Lupin Limited | 29.21 Billion INR | 98.879% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -1795.504% |
| Wockhardt Limited | 23.56 Billion INR | 98.61% |
| Vaishali Pharma Limited | 134.91 Million INR | -142.814% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 88.515% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -266.402% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 99.106% |
| FDC Limited | 205.18 Million INR | -59.661% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 98.364% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -3.519% |
| Eris Lifesciences Limited | 27.81 Billion INR | 98.822% |
| Venus Remedies Limited | 413.3 Million INR | 20.736% |
| ZIM Laboratories Limited | 1.08 Billion INR | 69.896% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 67.188% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -1562.944% |
| Shilpa Medicare Limited | 9.37 Billion INR | 96.505% |
| Albert David Limited | 33.24 Million INR | -885.5% |
| Ajanta Pharma Limited | 352.8 Million INR | 7.143% |
| Hester Biosciences Limited | 2.44 Billion INR | 86.595% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 49.597% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 96.761% |
| Gufic Biosciences Limited | 3.32 Billion INR | 90.16% |
| Windlas Biotech Limited | 36.41 Million INR | -799.753% |
| Procter & Gamble Health Limited | 95.6 Million INR | -242.678% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -4.49% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 66.739% |
| Granules India Limited | 13.15 Billion INR | 97.509% |
| Aarti Drugs Limited | 5.64 Billion INR | 94.194% |
| Bal Pharma Limited | 1.39 Billion INR | 76.541% |
| Alkem Laboratories Limited | 14.18 Billion INR | 97.69% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 98.999% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -2970.866% |
| Medicamen Biotech Limited | 308.17 Million INR | -6.304% |
| Unichem Laboratories Limited | 2.47 Billion INR | 86.764% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -34.321% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -7364.115% |
| Valiant Laboratories Limited | 767.08 Million INR | 57.293% |
| Orchid Pharma Limited | 1.35 Billion INR | 75.766% |
| Medico Remedies Limited | 80.5 Million INR | -306.936% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -97.093% |
| Ipca Laboratories Limited | 14.38 Billion INR | 97.722% |
| Brooks Laboratories Limited | 56.41 Million INR | -480.655% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 54.805% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.939% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 99.185% |
| NATCO Pharma Limited | 3.71 Billion INR | 91.175% |
| Suven Life Sciences Limited | 7.09 Million INR | -4516.035% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 83.064% |
| Strides Pharma Science Limited | 25.16 Billion INR | 98.698% |
| Indoco Remedies Limited | 6.71 Billion INR | 95.125% |
| Alpa Laboratories Limited | 52.46 Million INR | -524.416% |
| Lasa Supergenerics Limited | 220.76 Million INR | -48.395% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | 46.427% |